Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia

Brian T. Brinkerhoff, Nicholas W. Choong, Jonathan S. Treisman, David M. Poetker

Research output: Contribution to journalArticlepeer-review

9 Scopus citations


Current treatment of severe epistaxis in patients with hereditary hemorrhagic telangiectasia is not durable in reducing the frequency and severity of bleeds. Recent reports have demonstrated marked improvement of epistaxis with administration of either intravenous or topical bevacizumab. We present the long-term outcome of a patient who received repeated treatments of intravenous bevacizumab followed by maintenance intranasal bevacizumab. We demonstrate durable control of epistaxis with intranasal bevacizumab. This allows delivery of bevacizumab effectively, reduces cost, and obviates the risk of systemic adverse effects related to bevacizumab.

Original languageEnglish (US)
Pages (from-to)349-351
Number of pages3
JournalAmerican Journal of Otolaryngology - Head and Neck Medicine and Surgery
Issue number3
StatePublished - May 2012
Externally publishedYes

ASJC Scopus subject areas

  • Otorhinolaryngology


Dive into the research topics of 'Intravenous and topical intranasal bevacizumab (Avastin) in hereditary hemorrhagic telangiectasia'. Together they form a unique fingerprint.

Cite this